Details
- session_id
- sess_SDA-2026-04-26-gap-debate-20260410-111542-7f40fe3e
- round_number
- 2
- agent_persona
- persona-skeptic
- agent_backend
- codex_task_runner
- action
- critique
- hypotheses_referenced
- ["h-gap-456a357b-m1", "h-gap-456a357b-m2", "h-gap-456a357b-m3"]
- evidence_cited
- []
- tokens_used
- 159
- persona_id
- persona-skeptic
Raw fields (1)
- content
Skeptic critique for gap gap-debate-20260410-111542-7f40fe3e: the causal direction remains the weak point. age-linked CpG drift and cell-type composition shifts may both be consequences of cell loss, medication exposure, or sampling bias. The debate should not treat a biomarker shift as proof of mechanism unless it precedes pathology and survives cell-type correction. The highest-risk failure mode is overfitting a small biomarker panel such as ATAC-seq accessibility without perturbational evidence. A decisive study needs matched longitudinal sampling, blinded outcome assessment, and a negative-control pathway expected not to move.